RIVASTIGMINE PATCH 15 DIN 02479567
Health Canada record
| Active ingredient(s) | RIVASTIGMINE 13.3 MG |
|---|---|
| Dosage form | Patch |
| Route | Transdermal |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N06DA03 RIVASTIGMINE |
| Original market date | 15-Apr-2021 |
| Current status date | 31-Jul-2024 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pharmascience Inc. — licence 100241, currently licensed, last inspection rating C (2025-03-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RIVASTIGMINE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02302853 | EXELON PATCH 10 | KNIGHT THERAPEUTICS INC. | Patch | RIVASTIGMINE 9.5 MG | Marketed |
| 02432803 | EXELON PATCH 15 | KNIGHT THERAPEUTICS INC. | Patch | RIVASTIGMINE 13.3 MG | Marketed |
| 02302845 | EXELON PATCH 5 | KNIGHT THERAPEUTICS INC. | Patch | RIVASTIGMINE 4.6 MG | Marketed |
| 02423421 | MYLAN-RIVASTIGMINE PATCH 10 | MYLAN PHARMACEUTICALS ULC | Patch | RIVASTIGMINE 9.5 MG | Marketed |
| 02423413 | MYLAN-RIVASTIGMINE PATCH 5 | MYLAN PHARMACEUTICALS ULC | Patch | RIVASTIGMINE 4.6 MG | Marketed |
| 02426307 | SANDOZ RIVASTIGMINE PATCH 10 | SANDOZ CANADA INCORPORATED | Patch | RIVASTIGMINE 9.5 MG | Marketed |
| 02426293 | SANDOZ RIVASTIGMINE PATCH 5 | SANDOZ CANADA INCORPORATED | Patch | RIVASTIGMINE 4.6 MG | Marketed |
| 02423537 | ACT RIVASTIGMINE PATCH 10 | ACTAVIS PHARMA COMPANY | Patch | RIVASTIGMINE 18 MG | Cancelled Pre Market |
| 02423529 | ACT RIVASTIGMINE PATCH 5 | ACTAVIS PHARMA COMPANY | Patch | RIVASTIGMINE 9 MG | Cancelled Pre Market |
| 02490188 | PRIVA-RIVASTIGMINE | PHARMAPAR INC | Patch | RIVASTIGMINE 13.3 MG | Cancelled Pre Market |
| 02490153 | PRIVA-RIVASTIGMINE | PHARMAPAR INC | Patch | RIVASTIGMINE 4.6 MG | Cancelled Pre Market |
| 02490161 | PRIVA-RIVASTIGMINE | PHARMAPAR INC | Patch | RIVASTIGMINE 9.5 MG | Cancelled Pre Market |
| 02479559 | RIVASTIGMINE PATCH 10 | PHARMASCIENCE INC | Patch | RIVASTIGMINE 9.5 MG | Dormant |
| 02479540 | RIVASTIGMINE PATCH 5 | PHARMASCIENCE INC | Patch | RIVASTIGMINE 4.6 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 32045 | 2023-11-07 | Abbreviated New Drug Submission (ANDS) | Administrative: Change in Product Ownership |
| 25097 | 2021-01-28 | Supplement to an Abbreviated New Drug Submission (SANDS) | PRODUCT NAME CHANGE. UPDATING THE PRODUCT MONOGRAPH AND PACKAGE INSERT |
| 21981 | 2019-03-18 | Abbreviated New Drug Submission (ANDS) | CHANGE IN PRODUCT OWNERSHIP |
| 21157 | 2018-07-30 | Abbreviated New Drug Submission (ANDS) |
International API supply for RIVASTIGMINE
9 valid EDQM Certificates of Suitability from 9 holders. 28 active FDA Drug Master Files.
Request a quote for RIVASTIGMINE PATCH 15